What development phase is Adalimumab plus different doses of oral glucocorticosteroid in?

Adalimumab plus different doses of oral glucocorticosteroid is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Adalimumab plus different doses of oral glucocorticosteroid

Peking Union Medical College Hospital · FDA-approved active Small molecule Quality 3/100

At a glance

Generic name	Adalimumab plus different doses of oral glucocorticosteroid
Also known as	Humira, prednisone
Sponsor	Peking Union Medical College Hospital
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Efficacy and Safety of Adalimumab Plus Medium Dose Oral Glucocorticosteroid for Refractory Behçet's Uveitis (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Adalimumab plus different doses of oral glucocorticosteroid CI brief — competitive landscape report
Adalimumab plus different doses of oral glucocorticosteroid updates RSS · CI watch RSS
Peking Union Medical College Hospital portfolio CI